6.65% of Recursion Pharmaceuticals stock is owned by insiders. Learn more on RXRX's insider holdings. Insiders have sold a total of 1,360,956 Recursion Pharmaceuticals shares in the last 24 months for ...

Abstract: Reconfigurable computing devices such as FPGAs offer application developers the ability to create solutions with a performance comparable to that of a hardware solution, but with the ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

AI startup Recursive has officially emerged from stealth, calling recursive self-improvement the "fastest path to superintelligence." "The fastest path to superintelligence will be realized by AI that ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...

Recursive Superintelligence aims to eliminate human intervention in the AI training process, creating a system that autonomously improves its own code and architecture. The round was led by GV (Google ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Birgitta Böckeler, Distinguished Engineer at ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...